GlassScriptPhysician profile
Timothy D Langford
NPI 1902871627
$132,917.92
in general payments reported to CMS, 2019-2025
37 companies · $235 in 2025
The $235 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $28K · 2021: $24K · 2022: $36K · 2023: $3,291 · 2024: $183 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,271 · Food and Beverage: $1,439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,270.73 |
| Food and Beverage | $1,438.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cryo Specialty Medical, LLC | $122,000.00 | 2019-2022 | |
| Palette Life Sciences, INC. | $2,108.13 | 2023 | |
| Coloplast Corp | $1,024.08 | 2020-2025 | Titan |
| Neotract INC. | $992.17 | 2019-2020 | |
| Teleflex LLC | $930.55 | 2021-2023 | Urolift |
| Boston Scientific Corporation | $921.82 | 2019-2025 | General - Erectile Dysfunction, Spaceoar Vue System - 10ml |
| Procept Biorobotics Corporation | $818.01 | 2019-2020 | |
| Intuitive Surgical, INC. | $722.22 | 2021-2022 | |
| Astellas Pharma US INC | $472.02 | 2019-2021 | |
| Pfizer INC. | $454.94 | 2019-2021 | |
| Dendreon Pharmaceuticals LLC | $315.89 | 2019-2021 | |
| Janssen Biotech, INC. | $242.83 | 2019-2021 | |
| Blue Earth Diagnostics | $185.35 | 2019-2021 | |
| Allergan, INC. | $184.97 | 2019-2021 | |
| Abbvie INC. | $180.07 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rochester Medical Corporation | $161.17 | 2021-2022 | |
| Myovant Sciences INC. | $143.17 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $142.08 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $123.85 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $100.84 | 2019-2021 | |
| Amgen INC. | $100.11 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $85.72 | 2023-2024 | Orgovyx |
| Ambu INC. | $72.83 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.31 | 2019-2021 | |
| Myriad Genetic Laboratories, INC. | $68.34 | 2020-2021 | |
| Ferring Pharmaceuticals INC. | $49.84 | 2019-2020 | |
| Davol INC. | $40.79 | 2020 | |
| Innovation Technologies INC | $38.72 | 2022 | |
| Axonics, INC. | $28.71 | 2020-2023 | Axonics |
| Tolmar Pharmaceuticals, INC. | $23.60 | 2019 | |
| Sun Pharmaceutical Industries INC. | $22.69 | 2020 | |
| Baudax Bio INC. | $22.57 | 2020 | |
| Karl Storz Endoscopy-America | $21.35 | 2022 | |
| Angiodynamics, INC. | $19.79 | 2024 | Nanoknife |
| Clovis Oncology, INC. | $16.36 | 2020 | |
| Edap Technomed INC | $13.03 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$288,464.73 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Langford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.